Completed PHASE3 INTERVENTIONAL 2-arm NCT01181167

A Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty

A Phase 3, Randomized, Double-Blind, Double-Dummy Efficacy and Safety Study of the Oral Factor Xa Inhibitor DU-176b Compared With Enoxaparin Sodium for Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty (STARS J-5 Trial)

Sponsor: Daiichi Sankyo Co., Ltd.

Conditions Prevention Venous Thromboembolism

Interventions edoxaban enoxaparin sodium

Updated 9 times since 2017 Last updated: Feb 8, 2019 Started: May 31, 2009 Primary completion: Jan 31, 2010 Completion: Mar 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Prevention and Venous Thromboembolism, this trial is completed. The trial is conducted by Daiichi Sankyo Co., Ltd. and has accumulated 9 data snapshots since 2009. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Mar 2024 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Mar 2024 [monthly]

Completed PHASE3
Apr 2019 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 4 earlier versions

Feb 2019 — Apr 2019 [monthly]

Completed PHASE3
Jun 2018 — Feb 2019 [monthly]

Completed PHASE3
Sep 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Sep 2017 [monthly]

Completed PHASE3

First recorded

May 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Daiichi Sankyo Co., Ltd.

Data source: Daiichi Sankyo

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Osaka, Japan
• Tokyo, Japan